INmune Bio, Inc.
INMB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $55,031 | $53,819 | $175,694 | $104,048 |
| - Cash | $27,734 | $33,374 | $19,337 | $20,922 |
| + Debt | $1,080 | $451 | $347 | $384 |
| Enterprise Value | $28,377 | $20,896 | $156,704 | $83,510 |
| Revenue | $0 | $0 | $50 | $0 |
| % Growth | – | -100% | – | – |
| Gross Profit | -$28 | $0 | $50 | $0 |
| % Margin | – | – | 100% | – |
| EBITDA | -$6,444 | -$8,057 | -$9,905 | -$9,218 |
| % Margin | – | – | -19,810% | – |
| Net Income | -$6,472 | -$24,458 | -$9,739 | -$9,218 |
| % Margin | – | – | -19,478% | – |
| EPS Diluted | -0.24 | -1.05 | -0.43 | -0.41 |
| % Growth | 77.1% | -144.2% | -4.9% | – |
| Operating Cash Flow | -$5,439 | -$7,375 | -$6,824 | -$11,013 |
| Capital Expenditures | -$193 | -$706 | $0 | $0 |
| Free Cash Flow | -$5,632 | -$8,081 | -$6,824 | -$11,013 |